2022-10 – Q3 2022 Reporting
Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…
Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…
European Patent office has Published a SER150 patent 19th October 2022Download
Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…
AGM 2022 to be postponed until late june 2022 Read more
Highlights SER150 clinical study in Australia is still delayed after Covid19 lockdownsSerodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.The Group qualified for and received a “Patent…
Announcement Release SER150 CL-009 Approval EC AustraliaDownload
Subscription Period to be extended until the 12th of May: Read more
Link Serodus Prospectus: Read more